7th Annual Heart in Diabetes (HiD) CME Conference

7th Annual Heart in Diabetes (HiD) CME Conference is organized by The Metabolic Institute of America (TMIOA) and will be held from Jun 09 - 11, 2023 at Hilton Philadelphia at Penn's Landing, Philadelphia, Pennsylvania, United States of America.

Program Description:
The Heart in Diabetes (HiD) conference, entering its seventh year, is a unique medical meeting that brings world-renowned clinical leaders in diabetes, obesity, and cardiorenal metabolic diseases together with practicing clinicians to improve the care of patients at a high risk of these comorbidities.

This program is designed to evaluate the clinical science aspects of recent cardiovascular outcome trials (CVOTs) and their impact on the prevention and treatment of diabetes, ASCVD, heart failure, kidney, and metabolic diseases. The goal is to develop appropriate comprehensive management plans aligning endocrinologists, cardiologists, nephrologists, and all other interested clinicians in their understanding of the new data’s implications on the clinical management of these very high-risk patients.

Learning Objectives:
Upon completion of this meeting, participants should be able to:
• Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome
• Be able to assess cardiovascular risk in diabetes with imaging and biomarkers with a focus on the CAC score
• Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as hyperglycemia
• Describe the optimal use of technology—especially  CGM—and digital technology and their impact on diabetes and CVD
• Be able to recognize and manage hypoglycemia and its impact on comorbidities
• Evaluate stroke and dementia in diabetes
• Discuss the impact of obesity and diets on the fatty liver, the kidney, and the heart
• Evaluate the evidence supporting the use of GLP1-RAs, SGLT2 inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D
• Understand new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD
• Discuss changes in management guidelines and the evolution of DCRM multispecialty management approaches
• Evaluate the impact on the clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies
• Recognize the impact of diabetes and CVD on the severity of COVID-19
• Describe the state of heart disease in women
• Discuss diabetes, CKD, CVD, and HF in diverse populations

Initiative/Goal:
• To develop a platform to address the clinical science of the Heart in Diabetes
• To identify the implications of state-of-the-art clinical research on cardiovascular, liver, and kidney disease in diabetes
• To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions